Skip to main content
. 2015 Jun 16;2015:865101. doi: 10.1155/2015/865101

Figure 1.

Figure 1

Pooled analysis of 1,861 ipilimumab-treated patients from 12 clinical trials [3]. Median overall survival was 11.4 months (95% CI: 10.7–12.1 months) and 3-year overall survival was 22% (95% CI: 20–24%).